(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 45.93% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Eton Pharmaceuticals's revenue in 2025 is $49,422,000.On average, 2 Wall Street analysts forecast ETON's revenue for 2025 to be $2,105,981,024, with the lowest ETON revenue forecast at $1,995,224,604, and the highest ETON revenue forecast at $2,216,737,443. On average, 2 Wall Street analysts forecast ETON's revenue for 2026 to be $3,114,186,252, with the lowest ETON revenue forecast at $2,959,314,987, and the highest ETON revenue forecast at $3,269,057,517.
In 2027, ETON is forecast to generate $4,118,502,938 in revenue, with the lowest revenue forecast at $3,832,493,927 and the highest revenue forecast at $4,404,511,948.